Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis
| Autor: | J. Rodriguez-Carbajal, F. Rubio-Donnadieu, P. Penagos, B. Torres, Julio Sotelo, Francisco Escobedo, O. H. Del Brutto |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.medical_treatment Neurocysticercosis Helminthiasis Spontaneous remission Albendazole Gastroenterology Drug Administration Schedule Praziquantel Pharmacotherapy Internal medicine parasitic diseases medicine Humans Aged Randomized Controlled Trials as Topic Chemotherapy Brain Diseases business.industry Cysticercosis Middle Aged medicine.disease Surgery Neurology Female Neurology (clinical) business Tomography X-Ray Computed medicine.drug |
| Zdroj: | Journal of neurology. 237(2) |
| ISSN: | 0340-5354 |
| Popis: | The efficacy of different regimens of therapy for parenchymal brain cysticercosis either with praziquantel (PZQ) or with albendazole (ALB) was compared in 114 patients. Four schemes of treatment were used: PZQ 50 mg/kg per day for 15 days, PZQ 50 mg/kg per day for 8 days, ALB 15 mg/kg per day for 30 days, and ALB 15 mg/kg per day for 8 days. Three months after therapy, it was apparent that both PZQ and ALB were effective, as shown by the disappearance of cystic lesions in computed tomographic scans. Thirty-three control patients followed for a mean of 11 months had no spontaneous remission of lesions. When comparing PZQ with ALB, the latter was found to be more effective than the former for both the full and the short course of treatment: 85% vs 60% and 85% vs 48% disappearance of lesions, respectively (P less than 0.001). Comparison of the full vs the short course of PZQ showed that the short course had a further 12% reduction in drug effectiveness. In contrast, the length of ALB therapy could be shortened without lessening its efficacy. Based on these results, an 8-day course of ALB is recommended as treatment for parenchymal brain cysticercosis; a 15-day course of PZQ could be subsequently used in those patients who show only partial response to ALB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink